Global Next Generation Sequencing (NGS) Data Analysis Market to Reach US$1.2 Billion by the Year 2026

Abstract: Global Next Generation Sequencing (NGS) Data Analysis Market to Reach US$1. 2 Billion by the Year 2026 . Next-generation sequencing (NGS) data analysis is widely used for investigating genomic and epigenomic patterns related to a wide range of biological processes.

New York, Jan. 14, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Next Generation Sequencing (NGS) Data Analysis Industry" - https://www.reportlinker.com/p06032337/?utm_source=GNW
NGS data analysis encompasses primary, secondary and tertiary analysis steps, with some of these stages holding potential for automation through new sequencing solutions. Growth in the global market is set to be driven due to extensive uptake of the technology for analysis of RNA and DNA sequences. Cloud-based platforms are rapidly emerging as favorable solutions for performing computationally intensive activities during NGS data analysis makes it fast and simple for researchers to acquire computational resources for conducting large-scale data analysis of NGS. Recent technological advancements in cloud computing and bioinformatics have led to the development of a wide array of cloud-based bioinformatics platforms and services for carrying out large-scale NGS data analysis, which is likely to propel significant market growth in the coming years. NGS methods are being extensively employed in genomic research, clinical diagnosis, and for oncology precision medicine, particularly for the diagnosis of breast and lung cancers. The rising prevalence of cancer cases across the globe is expected to boost growth in the global NGS data analysis market in the near future. Moreover, with tangible progress made towards personalized treatment of diseases, there is an increased demand for rapid and precise sequencing interpretation algorithms and tools that can help in expediting data analysis.

Amid the COVID-19 crisis, the global market for Next Generation Sequencing (NGS) Data Analysis estimated at US$549.2 Million in the year 2020, is projected to reach a revised size of US$1.2 Billion by 2026, growing at a CAGR of 14.1% over the analysis period. Services, one of the segments analyzed in the report, is projected to grow at a 14.9% CAGR to reach US$814.1 Million by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the NGS Commercial Software segment is readjusted to a revised 13% CAGR for the next 7-year period. This segment currently accounts for a 44% share of the global Next Generation Sequencing (NGS) Data Analysis market. Analytical software is expected to exhibit robust growth over the next few years, attributed to the increased awareness and growing demand for sequencing technologies. The vast quantities of data generated via NGS require management platforms and solutions, which is resulting in the rising demand for such algorithms and tools. Companies lacking the necessary infrastructure for data analysis, interpretation, and management are increasingly adopting cost-effective NGS data analysis services.

The U.S. Market is Estimated at $238.7 Million in 2021, While China is Forecast to Reach $128.6 Million by 2026

The Next Generation Sequencing (NGS) Data Analysis market in the U.S. is estimated at US$238.7 Million in the year 2021. The country currently accounts for a 37.6% share in the global market. China, the world`s second largest economy, is forecast to reach an estimated market size of US$128.6 Million in the year 2026 trailing a CAGR of 15.1% through the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 12.8% and 13.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 14.1% CAGR while Rest of European market (as defined in the study) will reach US$101.9 Million by the end of the analysis period. The US is a major regional market for NGS data analysis, attributed to the presence of several established players, growing demand for personalized medicine, and launch of several large-scale genome sequencing projects in the region. Europe represents another major market. The region`s dominance is attributed to the presence of several key global players, including Agilent Technologies, Illumina, and Thermo Fisher Scientific, coupled with the presence of a large number of regional players engaged in developing NGS data analysis software. There are also various European universities that are involved in conducting various NGS research projects, which is driving the adoption of NGS software tools in the region.


Select Competitors (Total 111 Featured)

• Agilent Technologies, Inc.

• Bio-Rad Laboratories, Inc.

• Congenica Ltd.

• DNAnexus Inc.

• Dnastar, Inc.

• Eurofins Scientific

• F. Hoffmann-La Roche Ltd.

• Fabric Genomics, Inc.

• Genuity Science

• Golden Helix, Inc.

• Illumina, Inc.

• Intrexon Bioinformatics Germany GmbH

• Pacific Biosciences of California, Inc.

• Partek Incorporated

• PierianDx

• Qiagen

• SciGenom Labs Pvt. Ltd.

• Sophia Genetics

• Thermo Fisher Scientific, Inc.

Read the full report: https://www.reportlinker.com/p06032337/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
NGS Data Analysis: Unraveling Critical Clues to Solve
Scientific Problems
NGS Data Analysis: Insights into File Formats & Downstream
Analysis
File Formats for NGS Raw Data
NGS Data: Downstream Analysis
Impact of Covid-19 and a Looming Global Recession
2020 Marked as a Year of Disruption & Transformation
The Never-Ending ?Race? Between the Virus & Vaccines Continues.
Amidst this Chaotic Battle, Where is the World Economy Heading
Now & Beyond?
Omicron Spreads Panic Worldwide; Omicron Variant Brings Back
Memories & Fears of the Worst Part of the 2020 Pandemic
EXHIBIT 1: Time is of Essence! What We Know So Far - ?Vaccine
Efficiency against New Strains is Decreasing?
Short-term Impact of Omicron on Travel
Financial Impact
Scientists Seek to Gather More Information on Omicron
Pharma Firms Aim to Improve Existing Vaccines to Counter Omicron
Omicron: Impact on Travel Industry
Steps taken by the Countries to Prevent Transmission of Omicron
Variant
With IMF Making an Upward Revision of Global GDP for 2021,
Companies Are Bullish About an Economic Comeback Despite a
Continuing Pandemic
EXHIBIT 2: A Strong Yet Exceedingly Patchy & Uncertain Recovery
Shaped by New Variants Comes Into Play: World Economic Growth
Projections (Real GDP, Annual % Change) for 2020 through 2022
Impact of COVID-19 on Next Generation Sequencing (NGS) Data
Analysis
Great Promise of NGS in Fight against COVID-19 Brings Spotlight
on NGS Data Analysis Market
Global Market Overview and Prospects
Next-Generation Sequencing (NGS) Data Analysis Market Witnesses
Burgeoning Growth
Key Market Drivers and Inhibitors
Market Analysis
US and Europe Lead, Asia-Pacific to Witness Growth
Analysis by Product
Analysis by Workflow
Analysis by Mode
Analysis by Read Length
Analysis by End-Use
Competitive Landscape
Recent Market Activity

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS
Growing Next Generation Sequencing Market Drives the Demand for
NGS Data Analysis
Increasing R&D Activities in NGS
Rising Use of NGS in Drug Discovery Drives Growth of NGS Data
Analysis
Rising Application of Whole Genome Sequencing Drives Demand for
Faster Secondary Analysis Tools
Technological Advancements in Sequencing Techniques and Data
Integration
Research Initiatives for the Development of NGS-based In-vitro
Diagnostics
The Need for Large-scale NGS Data Analysis Pushes for Cloud-
enabled Bioinformatics Services
NGS Data Analysis Using Big Data Gains Ground
Improving Regulatory & Reimbursement Scenario for NGS-based
Diagnostic Tests
Increase in Genome Mapping Programs
Declining Costs of Genome Sequencing Drive Market Growth
Growth of Long-Read Sequencing to Propel the Market for NGS
Data Analysis
Aging Demographics Present Opportunities
EXHIBIT 3: Expanding Elderly Population Worldwide: Breakdown of
Number of People Aged 65+ Years in Million by Geographic
Region for the Years 2019 and 2030
EXHIBIT 4: Elderly Population (65+ Years) as a % of Total
Population by Developed, Less Developed and Least Developed
Regions: 2019 & 2030
Growing Prevalence of Chronic Diseases to Boost the Market
Prospects
EXHIBIT 5: Rising Diabetes Prevalence: Number of Adults (20-79)
with Diabetes (in Millions) by Region for 2017 and 2045
EXHIBIT 6: Fatalities by Heart Conditions: Estimated Percentage
Breakdown for Cardiovascular Disease, Ischemic Heart Disease,
Stroke, and Others
EXHIBIT 7: Breakdown of Total Number of Cancer Cases by Region:
2020
EXHIBIT 8: Breakdown of Total Number of Cancer Cases by Type: 2020
Market Challenges

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Next Generation
Sequencing (NGS) Data Analysis by Geographic Region - USA,
Canada, Japan, China, Europe, Asia-Pacific and Rest of World
Markets - Independent Analysis of Annual Revenues in US$
Thousand for Years 2020 through 2027 and % CAGR

Table 2: World 7-Year Perspective for Next Generation
Sequencing (NGS) Data Analysis by Geographic Region -
Percentage Breakdown of Value Revenues for USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets for Years
2021 & 2027

Table 3: World Current & Future Analysis for Services by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Revenues in US$ Thousand for Years 2020 through 2027
and % CAGR

Table 4: World 7-Year Perspective for Services by Geographic
Region - Percentage Breakdown of Value Revenues for USA,
Canada, Japan, China, Europe, Asia-Pacific and Rest of World
for Years 2021 & 2027

Table 5: World Current & Future Analysis for Ngs Commercial
Software by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Revenues in US$ Thousand for Years 2020
through 2027 and % CAGR

Table 6: World 7-Year Perspective for Ngs Commercial Software
by Geographic Region - Percentage Breakdown of Value Revenues
for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2021 & 2027

Table 7: World Current & Future Analysis for Tertiary Data
Analysis by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Revenues in US$ Thousand for Years 2020
through 2027 and % CAGR

Table 8: World 7-Year Perspective for Tertiary Data Analysis by
Geographic Region - Percentage Breakdown of Value Revenues for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2021 & 2027

Table 9: World Current & Future Analysis for Primary Data
Analysis by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Revenues in US$ Thousand for Years 2020
through 2027 and % CAGR

Table 10: World 7-Year Perspective for Primary Data Analysis by
Geographic Region - Percentage Breakdown of Value Revenues for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2021 & 2027

Table 11: World Current & Future Analysis for Secondary Data
Analysis by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Revenues in US$ Thousand for Years 2020
through 2027 and % CAGR

Table 12: World 7-Year Perspective for Secondary Data Analysis
by Geographic Region - Percentage Breakdown of Value Revenues
for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2021 & 2027

Table 13: World Current & Future Analysis for In-House by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Revenues in US$ Thousand for Years 2020 through 2027
and % CAGR

Table 14: World 7-Year Perspective for In-House by Geographic
Region - Percentage Breakdown of Value Revenues for USA,
Canada, Japan, China, Europe, Asia-Pacific and Rest of World
for Years 2021 & 2027

Table 15: World Current & Future Analysis for Outsourced by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Revenues in US$ Thousand for Years 2020 through 2027
and % CAGR

Table 16: World 7-Year Perspective for Outsourced by Geographic
Region - Percentage Breakdown of Value Revenues for USA,
Canada, Japan, China, Europe, Asia-Pacific and Rest of World
for Years 2021 & 2027

Table 17: World Current & Future Analysis for Academic Research
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Revenues in US$ Thousand for Years 2020 through 2027
and % CAGR

Table 18: World 7-Year Perspective for Academic Research by
Geographic Region - Percentage Breakdown of Value Revenues for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2021 & 2027

Table 19: World Current & Future Analysis for Clinical Research
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Revenues in US$ Thousand for Years 2020 through 2027
and % CAGR

Table 20: World 7-Year Perspective for Clinical Research by
Geographic Region - Percentage Breakdown of Value Revenues for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2021 & 2027

Table 21: World Current & Future Analysis for Hospitals &
Clinics by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Revenues in US$ Thousand for Years 2020
through 2027 and % CAGR

Table 22: World 7-Year Perspective for Hospitals & Clinics by
Geographic Region - Percentage Breakdown of Value Revenues for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2021 & 2027

Table 23: World Current & Future Analysis for Pharma & Biotech
Entities by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Revenues in US$ Thousand for Years 2020
through 2027 and % CAGR

Table 24: World 7-Year Perspective for Pharma & Biotech
Entities by Geographic Region - Percentage Breakdown of Value
Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific
and Rest of World for Years 2021 & 2027

Table 25: World Current & Future Analysis for Other End-Uses by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Revenues in US$ Thousand for Years 2020 through 2027
and % CAGR

Table 26: World 7-Year Perspective for Other End-Uses by
Geographic Region - Percentage Breakdown of Value Revenues for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2021 & 2027

III. MARKET ANALYSIS

UNITED STATES
Table 27: USA Current & Future Analysis for Next Generation
Sequencing (NGS) Data Analysis by Component - Services and Ngs
Commercial Software - Independent Analysis of Annual Revenues
in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 28: USA 7-Year Perspective for Next Generation Sequencing
(NGS) Data Analysis by Component - Percentage Breakdown of
Value Revenues for Services and Ngs Commercial Software for the
Years 2021 & 2027

Table 29: USA Current & Future Analysis for Next Generation
Sequencing (NGS) Data Analysis by Workflow - Tertiary Data
Analysis, Primary Data Analysis and Secondary Data Analysis -
Independent Analysis of Annual Revenues in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 30: USA 7-Year Perspective for Next Generation Sequencing
(NGS) Data Analysis by Workflow - Percentage Breakdown of Value
Revenues for Tertiary Data Analysis, Primary Data Analysis and
Secondary Data Analysis for the Years 2021 & 2027

Table 31: USA Current & Future Analysis for Next Generation
Sequencing (NGS) Data Analysis by Mode - In-House and
Outsourced - Independent Analysis of Annual Revenues in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 32: USA 7-Year Perspective for Next Generation Sequencing
(NGS) Data Analysis by Mode - Percentage Breakdown of Value
Revenues for In-House and Outsourced for the Years 2021 & 2027

Table 33: USA Current & Future Analysis for Next Generation
Sequencing (NGS) Data Analysis by End-Use - Academic Research,
Clinical Research, Hospitals & Clinics, Pharma & Biotech
Entities and Other End-Uses - Independent Analysis of Annual
Revenues in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 34: USA 7-Year Perspective for Next Generation Sequencing
(NGS) Data Analysis by End-Use - Percentage Breakdown of Value
Revenues for Academic Research, Clinical Research, Hospitals &
Clinics, Pharma & Biotech Entities and Other End-Uses for the
Years 2021 & 2027

CANADA
Table 35: Canada Current & Future Analysis for Next Generation
Sequencing (NGS) Data Analysis by Component - Services and Ngs
Commercial Software - Independent Analysis of Annual Revenues
in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 36: Canada 7-Year Perspective for Next Generation
Sequencing (NGS) Data Analysis by Component - Percentage
Breakdown of Value Revenues for Services and Ngs Commercial
Software for the Years 2021 & 2027

Table 37: Canada Current & Future Analysis for Next Generation
Sequencing (NGS) Data Analysis by Workflow - Tertiary Data
Analysis, Primary Data Analysis and Secondary Data Analysis -
Independent Analysis of Annual Revenues in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 38: Canada 7-Year Perspective for Next Generation
Sequencing (NGS) Data Analysis by Workflow - Percentage
Breakdown of Value Revenues for Tertiary Data Analysis, Primary
Data Analysis and Secondary Data Analysis for the Years 2021 &
2027

Table 39: Canada Current & Future Analysis for Next Generation
Sequencing (NGS) Data Analysis by Mode - In-House and
Outsourced - Independent Analysis of Annual Revenues in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 40: Canada 7-Year Perspective for Next Generation
Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown
of Value Revenues for In-House and Outsourced for the Years
2021 & 2027

Table 41: Canada Current & Future Analysis for Next Generation
Sequencing (NGS) Data Analysis by End-Use - Academic Research,
Clinical Research, Hospitals & Clinics, Pharma & Biotech
Entities and Other End-Uses - Independent Analysis of Annual
Revenues in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 42: Canada 7-Year Perspective for Next Generation
Sequencing (NGS) Data Analysis by End-Use - Percentage
Breakdown of Value Revenues for Academic Research, Clinical
Research, Hospitals & Clinics, Pharma & Biotech Entities and
Other End-Uses for the Years 2021 & 2027

JAPAN
Table 43: Japan Current & Future Analysis for Next Generation
Sequencing (NGS) Data Analysis by Component - Services and Ngs
Commercial Software - Independent Analysis of Annual Revenues
in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 44: Japan 7-Year Perspective for Next Generation
Sequencing (NGS) Data Analysis by Component - Percentage
Breakdown of Value Revenues for Services and Ngs Commercial
Software for the Years 2021 & 2027

Table 45: Japan Current & Future Analysis for Next Generation
Sequencing (NGS) Data Analysis by Workflow - Tertiary Data
Analysis, Primary Data Analysis and Secondary Data Analysis -
Independent Analysis of Annual Revenues in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 46: Japan 7-Year Perspective for Next Generation
Sequencing (NGS) Data Analysis by Workflow - Percentage
Breakdown of Value Revenues for Tertiary Data Analysis, Primary
Data Analysis and Secondary Data Analysis for the Years 2021 &
2027

Table 47: Japan Current & Future Analysis for Next Generation
Sequencing (NGS) Data Analysis by Mode - In-House and
Outsourced - Independent Analysis of Annual Revenues in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 48: Japan 7-Year Perspective for Next Generation
Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown
of Value Revenues for In-House and Outsourced for the Years
2021 & 2027

Table 49: Japan Current & Future Analysis for Next Generation
Sequencing (NGS) Data Analysis by End-Use - Academic Research,
Clinical Research, Hospitals & Clinics, Pharma & Biotech
Entities and Other End-Uses - Independent Analysis of Annual
Revenues in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 50: Japan 7-Year Perspective for Next Generation
Sequencing (NGS) Data Analysis by End-Use - Percentage
Breakdown of Value Revenues for Academic Research, Clinical
Research, Hospitals & Clinics, Pharma & Biotech Entities and
Other End-Uses for the Years 2021 & 2027

CHINA
Table 51: China Current & Future Analysis for Next Generation
Sequencing (NGS) Data Analysis by Component - Services and Ngs
Commercial Software - Independent Analysis of Annual Revenues
in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 52: China 7-Year Perspective for Next Generation
Sequencing (NGS) Data Analysis by Component - Percentage
Breakdown of Value Revenues for Services and Ngs Commercial
Software for the Years 2021 & 2027

Table 53: China Current & Future Analysis for Next Generation
Sequencing (NGS) Data Analysis by Workflow - Tertiary Data
Analysis, Primary Data Analysis and Secondary Data Analysis -
Independent Analysis of Annual Revenues in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 54: China 7-Year Perspective for Next Generation
Sequencing (NGS) Data Analysis by Workflow - Percentage
Breakdown of Value Revenues for Tertiary Data Analysis, Primary
Data Analysis and Secondary Data Analysis for the Years 2021 &
2027

Table 55: China Current & Future Analysis for Next Generation
Sequencing (NGS) Data Analysis by Mode - In-House and
Outsourced - Independent Analysis of Annual Revenues in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 56: China 7-Year Perspective for Next Generation
Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown
of Value Revenues for In-House and Outsourced for the Years
2021 & 2027

Table 57: China Current & Future Analysis for Next Generation
Sequencing (NGS) Data Analysis by End-Use - Academic Research,
Clinical Research, Hospitals & Clinics, Pharma & Biotech
Entities and Other End-Uses - Independent Analysis of Annual
Revenues in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 58: China 7-Year Perspective for Next Generation
Sequencing (NGS) Data Analysis by End-Use - Percentage
Breakdown of Value Revenues for Academic Research, Clinical
Research, Hospitals & Clinics, Pharma & Biotech Entities and
Other End-Uses for the Years 2021 & 2027

EUROPE
Table 59: Europe Current & Future Analysis for Next Generation
Sequencing (NGS) Data Analysis by Geographic Region - France,
Germany, Italy, UK and Rest of Europe Markets - Independent
Analysis of Annual Revenues in US$ Thousand for Years 2020
through 2027 and % CAGR

Table 60: Europe 7-Year Perspective for Next Generation
Sequencing (NGS) Data Analysis by Geographic Region -
Percentage Breakdown of Value Revenues for France, Germany,
Italy, UK and Rest of Europe Markets for Years 2021 & 2027

Table 61: Europe Current & Future Analysis for Next Generation
Sequencing (NGS) Data Analysis by Component - Services and Ngs
Commercial Software - Independent Analysis of Annual Revenues
in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 62: Europe 7-Year Perspective for Next Generation
Sequencing (NGS) Data Analysis by Component - Percentage
Breakdown of Value Revenues for Services and Ngs Commercial
Software for the Years 2021 & 2027

Table 63: Europe Current & Future Analysis for Next Generation
Sequencing (NGS) Data Analysis by Workflow - Tertiary Data
Analysis, Primary Data Analysis and Secondary Data Analysis -
Independent Analysis of Annual Revenues in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 64: Europe 7-Year Perspective for Next Generation
Sequencing (NGS) Data Analysis by Workflow - Percentage
Breakdown of Value Revenues for Tertiary Data Analysis, Primary
Data Analysis and Secondary Data Analysis for the Years 2021 &
2027

Table 65: Europe Current & Future Analysis for Next Generation
Sequencing (NGS) Data Analysis by Mode - In-House and
Outsourced - Independent Analysis of Annual Revenues in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 66: Europe 7-Year Perspective for Next Generation
Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown
of Value Revenues for In-House and Outsourced for the Years
2021 & 2027

Table 67: Europe Current & Future Analysis for Next Generation
Sequencing (NGS) Data Analysis by End-Use - Academic Research,
Clinical Research, Hospitals & Clinics, Pharma & Biotech
Entities and Other End-Uses - Independent Analysis of Annual
Revenues in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 68: Europe 7-Year Perspective for Next Generation
Sequencing (NGS) Data Analysis by End-Use - Percentage
Breakdown of Value Revenues for Academic Research, Clinical
Research, Hospitals & Clinics, Pharma & Biotech Entities and
Other End-Uses for the Years 2021 & 2027

FRANCE
Table 69: France Current & Future Analysis for Next Generation
Sequencing (NGS) Data Analysis by Component - Services and Ngs
Commercial Software - Independent Analysis of Annual Revenues
in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 70: France 7-Year Perspective for Next Generation
Sequencing (NGS) Data Analysis by Component - Percentage
Breakdown of Value Revenues for Services and Ngs Commercial
Software for the Years 2021 & 2027

Table 71: France Current & Future Analysis for Next Generation
Sequencing (NGS) Data Analysis by Workflow - Tertiary Data
Analysis, Primary Data Analysis and Secondary Data Analysis -
Independent Analysis of Annual Revenues in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 72: France 7-Year Perspective for Next Generation
Sequencing (NGS) Data Analysis by Workflow - Percentage
Breakdown of Value Revenues for Tertiary Data Analysis, Primary
Data Analysis and Secondary Data Analysis for the Years 2021 &
2027

Table 73: France Current & Future Analysis for Next Generation
Sequencing (NGS) Data Analysis by Mode - In-House and
Outsourced - Independent Analysis of Annual Revenues in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 74: France 7-Year Perspective for Next Generation
Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown
of Value Revenues for In-House and Outsourced for the Years
2021 & 2027

Table 75: France Current & Future Analysis for Next Generation
Sequencing (NGS) Data Analysis by End-Use - Academic Research,
Clinical Research, Hospitals & Clinics, Pharma & Biotech
Entities and Other End-Uses - Independent Analysis of Annual
Revenues in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 76: France 7-Year Perspective for Next Generation
Sequencing (NGS) Data Analysis by End-Use - Percentage
Breakdown of Value Revenues for Academic Research, Clinical
Research, Hospitals & Clinics, Pharma & Biotech Entities and
Other End-Uses for the Years 2021 & 2027

GERMANY
Table 77: Germany Current & Future Analysis for Next Generation
Sequencing (NGS) Data Analysis by Component - Services and Ngs
Commercial Software - Independent Analysis of Annual Revenues
in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 78: Germany 7-Year Perspective for Next Generation
Sequencing (NGS) Data Analysis by Component - Percentage
Breakdown of Value Revenues for Services and Ngs Commercial
Software for the Years 2021 & 2027

Table 79: Germany Current & Future Analysis for Next Generation
Sequencing (NGS) Data Analysis by Workflow - Tertiary Data
Analysis, Primary Data Analysis and Secondary Data Analysis -
Independent Analysis of Annual Revenues in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 80: Germany 7-Year Perspective for Next Generation
Sequencing (NGS) Data Analysis by Workflow - Percentage
Breakdown of Value Revenues for Tertiary Data Analysis, Primary
Data Analysis and Secondary Data Analysis for the Years 2021 &
2027

Table 81: Germany Current & Future Analysis for Next Generation
Sequencing (NGS) Data Analysis by Mode - In-House and
Outsourced - Independent Analysis of Annual Revenues in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 82: Germany 7-Year Perspective for Next Generation
Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown
of Value Revenues for In-House and Outsourced for the Years
2021 & 2027

Table 83: Germany Current & Future Analysis for Next Generation
Sequencing (NGS) Data Analysis by End-Use - Academic Research,
Clinical Research, Hospitals & Clinics, Pharma & Biotech
Entities and Other End-Uses - Independent Analysis of Annual
Revenues in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 84: Germany 7-Year Perspective for Next Generation
Sequencing (NGS) Data Analysis by End-Use - Percentage
Breakdown of Value Revenues for Academic Research, Clinical
Research, Hospitals & Clinics, Pharma & Biotech Entities and
Other End-Uses for the Years 2021 & 2027

ITALY
Table 85: Italy Current & Future Analysis for Next Generation
Sequencing (NGS) Data Analysis by Component - Services and Ngs
Commercial Software - Independent Analysis of Annual Revenues
in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 86: Italy 7-Year Perspective for Next Generation
Sequencing (NGS) Data Analysis by Component - Percentage
Breakdown of Value Revenues for Services and Ngs Commercial
Software for the Years 2021 & 2027

Table 87: Italy Current & Future Analysis for Next Generation
Sequencing (NGS) Data Analysis by Workflow - Tertiary Data
Analysis, Primary Data Analysis and Secondary Data Analysis -
Independent Analysis of Annual Revenues in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 88: Italy 7-Year Perspective for Next Generation
Sequencing (NGS) Data Analysis by Workflow - Percentage
Breakdown of Value Revenues for Tertiary Data Analysis, Primary
Data Analysis and Secondary Data Analysis for the Years 2021 &
2027

Table 89: Italy Current & Future Analysis for Next Generation
Sequencing (NGS) Data Analysis by Mode - In-House and
Outsourced - Independent Analysis of Annual Revenues in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 90: Italy 7-Year Perspective for Next Generation
Sequencing (NGS) Data Analysis by Mode - Percentage Breakdown
of Value Revenues for In-House and Outsourced for the Years
2021 & 2027

Table 91: Italy Current & Future Analysis for Next Generation
Sequencing (NGS) Data Analysis by End-Use - Academic Research,
Clinical Research, Hospitals & Clinics, Pharma & Biotech
Entities and Other End-Uses - Independent Analysis of Annual
Revenues in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 92: Italy 7-Year Perspective for Next Generation
Sequencing (NGS) Data Analysis by End-Use - Percentage
Breakdown of Value Revenues for Academic Research, Clinical
Research, Hospitals & Clinics, Pharma & Biotech Entities and
Other End-Uses for the Years 2021 & 2027

UNITED KINGDOM
Table 93: UK Current & Future Analysis for Next Generation
Sequencing (NGS) Data Analysis by Component - Services and Ngs
Commercial Software - Independent Analysis of Annual Revenues
in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 94: UK 7-Year Perspective for Next Generation Sequencing
(NGS) Data Analysis by Component - Percentage Breakdown of
Value Revenues for Services and Ngs Commercial Software for the
Years 2021 & 2027

Table 95: UK Current & Future Analysis for Next Generation
Sequencing (NGS) Data Analysis by Workflow - Tertiary Data
Analysis, Primary Data Analysis and Secondary Data Analysis -
Independent Analysis of Annual Revenues in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 96: UK 7-Year Perspective for Next Generation Sequencing
(NGS) Data Analysis by Workflow - Percentage Breakdown of Value
Revenues for Tertiary Data Analysis, Primary Data Analysis and
Secondary Data Analysis for the Years 2021 & 2027

Table 97: UK Current & Future Analysis for Next Generation
Sequencing (NGS) Data Analysis by Mode - In-House and
Outsourced - Independent Analysis of Annual Revenues in US$

Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p06032337/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001